AI assistant
OPKO Health Inc. — Director's Dealing 2021
Sep 18, 2021
6963_rns_2021-09-18_5d5ffc92-b850-4984-99ae-75d7f7b08873.pdf
Director's Dealing
Open in viewerOpens in your device viewer
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
Check this box if no longer subject to Section 16. Form 4 or
Instruction 1(b).
Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person PHILLIP M.D. FROST ET AL |
2. Issuer Name and Ticker or Trading Symbol OPKO Health, Inc. [OPK] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X X Director 10% Owner |
|||||
|---|---|---|---|---|---|---|---|
| (Last) OPKO Health, Inc. 4400 Biscayne Blvd. |
(First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 09/14/2021 |
Officer (give title below)____ Other (specify below) X CEO & Chairman |
|||
| (Street) Miami (City) |
FL (State) |
33137 (Zip) |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) ____ Form filed by One Reporting Person X Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1.Title of Security (Instr. 3) |
2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| (Month/Day/Year) | Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
||
| Common Stock | 3,068,951 | D | ||||||||
| Common Stock | 09/14/2021 | P | 500 | A | \$3.445 | 193,072,194 | I | See Footnote (1) |
||
| Common Stock | 09/14/2021 | P | 5,825 | A | \$3.449 | 193,078,019 | I | See Footnote (1) |
||
| See |
| Common Stock | 09/14/2021 | P | 21,905 | A | \$3.45 | 193,099,924 | I | Footnote (1) |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 09/14/2021 | P | 10,100 | A | \$3.455 | 193,110,024 | I | See Footnote (1) |
| Common Stock | 09/14/2021 | P | 400 | A | \$3.465 | 193,110,424 | I | See Footnote (1) |
| Common Stock | 09/14/2021 | P | 44,085 | A | \$3.47 | 193,154,509 | I | See Footnote (1) |
| Common Stock | 09/14/2021 | P | 400 | A | \$3.475 | 193,154,909 | I | See Footnote (1) |
| Common Stock | 09/14/2021 | P | 16,785 | A | \$3.48 | 193,171,694 | I | See Footnote (1) |
| Common Stock | 30,127,177 | I | See Footnote (2) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 5. Number | 6. Date Exercisable and | 7. Title and | 8. Price of | 9. Number of | 10. | 11. Nature | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Security | Derivative | Conversion or Exercise |
Date (Month/Day/Year) |
Execution Date, if any |
Transaction Code |
of Derivative |
Expiration Date (Month/Day/Year) |
Amount of Underlying |
Derivative Security |
Derivative Securities |
Ownership Form of |
of Indirect Beneficial |
||||
| (Instr. 3) | Price of Derivative |
(Month/Day/Year) | (Instr. 8) | Acquired | Securities | Securities (Instr. 3 and 4) |
(Instr. 5) | Beneficially Owned |
Derivative Security: |
Ownership (Instr. 4) |
||||||
| Security | (A) or | Following | Direct (D) | |||||||||||||
| (D) | Disposed of | Reported Transaction(s) |
or Indirect (I) |
|||||||||||||
| (Instr. 3, 4, and 5) |
(Instr. 4) | (Instr. 4) | ||||||||||||||
| Amount | ||||||||||||||||
| Date | Expiration | or Number |
||||||||||||||
| Code | V | (A) | (D) | Exercisable | Date | Title | of Shares |
| Relationships | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | |||||
| FROST PHILLIP M.D. ET AL OPKO Health, Inc. 4400 Biscayne Blvd. Miami, FL 33137 |
X | X | CEO & Chairman | ||||||
| Frost Gamma Investments Trust 4400 Biscayne Blvd. Miami, FL 33137 |
X |
Explanation of Responses:
- (1) The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- (2) These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole
and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Phillip Frost, M.D., Individually and as Trustee 09/15/2021
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
JOINT FILER INFORMATION
Name: Frost Gamma Investments Trust
Address: 4400 Biscayne Blvd. Miami, FL 33137
Designated Filer: Phillip Frost, M.D.
Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)
Date of Earliest Transaction: September 14, 2021
Relationship to Issuer: 10% Owner
FROST GAMMA INVESTMENTS TRUST
By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee